Works matching IS 0030-2414 AND VI 103 AND IP 6 AND DT 2025

Results: 11
    1

    Front & Back Matter.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 1, doi. 10.1159/000546844
    Publication type:
    Article
    2

    Erratum.

    Published in:
    2025
    Publication type:
    Correction Notice
    3

    Retraction Statement.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 546, doi. 10.1159/000543881
    Publication type:
    Article
    4
    5

    The Immune Microenvironment in Prostate Cancer: A Comprehensive Review.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 521, doi. 10.1159/000541881
    By:
    • Novysedlak, Rene;
    • Guney, Miray;
    • Al Khouri, Majd;
    • Bartolini, Robin;
    • Koumbas Foley, Lily;
    • Benesova, Iva;
    • Ozaniak, Andrej;
    • Novak, Vojtech;
    • Vesely, Stepan;
    • Pacas, Pavel;
    • Buchler, Tomas;
    • Ozaniak Strizova, Zuzana
    Publication type:
    Article
    6
    7
    8
    9

    Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 469, doi. 10.1159/000541544
    By:
    • Nakazawa, Nobuhiro;
    • Sano, Akihiko;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Shiraishi, Takuya;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Article
    10

    Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 490, doi. 10.1159/000541250
    By:
    • LaPelusa, Michael;
    • Chamseddine, Shadi;
    • Tran Cao, Hop Sanderson;
    • Xiao, Lianchun;
    • Hasanov, Elshad;
    • Bhosale, Priya;
    • Amin, Hesham M.;
    • Mohamed, Yehia I.;
    • Gok Yavuz, Betul;
    • Sakr, Yara;
    • Xu, Li;
    • Hu, Ian;
    • Lee, Sunyoung S.;
    • Sakamuri, Divya;
    • Jindal, Sonali;
    • Nguyen, Van;
    • Curran, Michael A.;
    • Sun, Ryan;
    • Rashid, Asif;
    • Duda, Dan Gabriel
    Publication type:
    Article
    11

    Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 456, doi. 10.1159/000541018
    By:
    • Persano, Mara;
    • Casadei-Gardini, Andrea;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Rossari, Federico;
    • Yoo, Changhoon;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Masi, Gianluca;
    • Bergamo, Francesca;
    • Amadeo, Elisabeth;
    • Vitiello, Francesco;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko
    Publication type:
    Article